Herpes zoster: Risk and prevention during immunomodulating therapy.
about
Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis.The risk of herpes zoster in patients with ankylosing spondylitis: Analysis of the Korean National Health Insurance Service - Sample cohort database.Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges.
P2860
Herpes zoster: Risk and prevention during immunomodulating therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Herpes zoster: Risk and prevention during immunomodulating therapy.
@en
type
label
Herpes zoster: Risk and prevention during immunomodulating therapy.
@en
prefLabel
Herpes zoster: Risk and prevention during immunomodulating therapy.
@en
P2093
P1433
P1476
Herpes zoster: Risk and prevention during immunomodulating therapy.
@en
P2093
Alexandra Ducancelle
Charles Masson
Cong Tri Tran
Françoise Lunel-Fabiani
P356
10.1016/J.JBSPIN.2016.04.001
P577
2016-05-27T00:00:00Z